Tumor Biology

, Volume 37, Issue 11, pp 14939–14947 | Cite as

The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma

  • Ling Wang
  • Fu-biao Kang
  • Nan Sun
  • Juan Wang
  • Wei Chen
  • Dong Li
  • Bao-en ShanEmail author
Original Article


Our previous studies have shown that the expression level of B7 homolog 3 (B7-H3) was correlated with clinical staging and prognosis of osteosarcoma (OS) patients, and its silencing inhibited the proliferation and invasion of OS cells in vitro. However, its overexpression mechanism behind was far from elucidated. On the basis of bioinformatics and the preliminary screening data, we hypothesized that miR-124 might play an important role in OS development and as a lead candidate for modulating B7-H3 expression. In this study, we found that miR-124 was downregulated significantly in OS tumor tissue, compared to normal adjacent tissues (NATs). Lower miR-124 expression levels were associated with advanced Ennecking stage, lower tumor differentiation, and common pulmonary metastasis. The 5-year overall survival rate in the miR-124 upregulated group was 61.5 %, while with low miR-124 expression, only 11.8 % survived. Further studies in vitro showed that B7-H3 was a direct target of miR-124. Overexpression of miR-124 decreased B7-H3 mRNA and protein level and inhibited B7-H3 3′-UTR reporter activity. Treatment of OS cells with miR-124 mimics induced the inhibition of cell growth and invasion in vitro, which could be abrogated by transfected by B7-H3 expression vector. Our findings highlight the potential application of miR-124 as a novel onco-miRNA in OS, and its oncogenic effects are mediated chiefly through downregulation of B7-H3, thus suggesting a model for identifying miR-124 that can be exploited to improve the therapeutic potential efficacy of mAb targeting to B7-H3.


Osteosarcoma miR-124 B7-H3 Proliferation Invasion 



This program was financially supported by the National Natural Science Foundation of China (81402228), Hebei Natural Science Foundation (H2015206216), HeBei Province Medical Foundation (ZL20140334), and HeBei Province Education Foundation (QN2014049).

Compliance with ethical standards

Conflicts of interest


Authors’ contributions

The conception and design were initiated by FBK and LW; NS, JW, and WC performed clinical data acquisition and drafted the manuscript; DL contributed in the statistical analysis; BES directed the study and helped revised the paper. All authors read and approved the final manuscript.


  1. 1.
    Benjamin RS. Osteosarcoma: better treatment through better trial design. The Lancet Oncology. 2015;16(1):12–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Berner K, Johannesen TB, Bruland OS. Clinical epidemiology of low-grade and dedifferentiated osteosarcoma in Norway during 1975 and 2009. Sarcoma. 2015;2015:917679.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Reed DE, Shokat KM. Targeting osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):18100–1.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bagcchi S. Osteosarcoma survivors’ risk of second cancer. The Lancet Oncology. 2014;15(10):e425.CrossRefPubMedGoogle Scholar
  5. 5.
    Atkins MB, Larkin J. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst. 2016;108(6).Google Scholar
  6. 6.
    Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nature reviews Clinical oncology. 2016;13(1):25–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Bourzac K. Therapy: an immune one-two punch. Nature. 2015;528(7582):S134–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128–38.CrossRefPubMedGoogle Scholar
  9. 9.
    You S. Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. Front Immunol. 2015;6:242.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Depoil D, Dustin ML. Force and affinity in ligand discrimination by the TCR. Trends Immunol. 2014;35(12):597–603.CrossRefPubMedGoogle Scholar
  11. 11.
    Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Leung J, Suh WK. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune network. 2014;14(6):265–76.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, Cao N, Liu L, Zhang Y. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One. 2013;8(8):e70689.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer discovery. 2016;6(3):235–46.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li T, Mo X, Fu L, Xiao B, Guo J: Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget 2016.Google Scholar
  16. 16.
    Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene. 2015;34(24):3085–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Judice CC, Bourgard C, Kayano AC, Albrecht L, Costa FT. MicroRNAs in the host-apicomplexan parasites interactions: a review of immunopathological aspects. Frontiers in cellular and infection microbiology. 2016;6:5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Xiao Y, Wang J, Yan W, Zhou Y, Chen Y, Zhou K, Wen J, Wang Y, Cai W. Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling. J Hepatol. 2015;62(4):889–96.CrossRefPubMedGoogle Scholar
  19. 19.
    Dueck A, Eichner A, Sixt M, Meister G. A miR-155-dependent microRNA hierarchy in dendritic cell maturation and macrophage activation. FEBS Lett. 2014;588(4):632–40.CrossRefPubMedGoogle Scholar
  20. 20.
    O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nygren MK, Tekle C, Ingebrigtsen VA, Makela R, Krohn M, Aure MR, Nunes-Xavier CE, Perala M, Tramm T, Alsner J, et al. Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer. 2014;110(8):2072–80.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69(15):6275–81.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y, Fan S, Liu Y. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem Biophys Res Commun. 2013;438(2):439–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE: Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2015.Google Scholar
  26. 26.
    Salunke AA, Shah J, Gupta N, Pandit J. Pathologic fracture in osteosarcoma: association with poorer overall survival. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016.Google Scholar
  27. 27.
    Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016;28(1):26–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol. 2004;173(9):5445–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: friend or foe? Int J Cancer. 2014;134(12):2764–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Arigami T, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011;102(5):1019–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Bachawal SV, Jensen KC, Wilson KE, Tian L, Lutz AM, Willmann JK. Breast cancer detection by B7-H3-targeted ultrasound molecular imaging. Cancer Res. 2015;75(12):2501–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011;186(3):1093–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA targeting to modulate tumor microenvironment. Frontiers in oncology. 2016.Google Scholar
  35. 35.
    Arora A, Singh S, Bhatt AN, Pandey S, Sandhir R, Dwarakanath BS. Interplay between metabolism and oncogenic process: role of microRNAs. Translational oncogenomics. 2015;7:11–27.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Qu Y, Pan S, Kang M, Dong R, Zhao J. MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015.Google Scholar
  37. 37.
    Bao Y, Chen B, Wu Q, Hu K, Xi X, Zhu W, Zhong X, Chen J: Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clinical and experimental medicine 2015.Google Scholar
  38. 38.
    Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang Y et al. miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget. 2016.Google Scholar
  39. 39.
    Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ et al: miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. Cancer Res 2015, 75(24):5309–5317.Google Scholar
  40. 40.
    Zu L, Xue Y, Wang J, Fu Y, Wang X, Xiao G, Hao M, Sun X, Wang Y, Fu G, et al. The feedback loop between miR-124 and TGF-beta pathway plays a significant role in non-small cell lung cancer metastasis. Carcinogenesis. 2016;37(3):333–43.CrossRefPubMedGoogle Scholar
  41. 41.
    Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm. 2016;2016:6058147.Google Scholar
  42. 42.
    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Oyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad O. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016;7(6):6891–901.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Liu H, Wang H, Liu X, Yu T. miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells. Biochem Biophys Res Commun. 2016;472(2):346–52.CrossRefPubMedGoogle Scholar
  45. 45.
    Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J, Lu J. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-beta signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Ling Wang
    • 1
    • 2
  • Fu-biao Kang
    • 3
  • Nan Sun
    • 4
  • Juan Wang
    • 2
  • Wei Chen
    • 2
  • Dong Li
    • 3
  • Bao-en Shan
    • 1
    Email author
  1. 1.Cancer Research Institutethe Fourth Hospital of Hebei Medical UniversityShijiazhuangPeople’s Republic of China
  2. 2.Department of OrthopedicsThe Third Hospital of Hebei Medical UniversityShijiazhuangChina
  3. 3.Department of Liver DiseasesBethune International Peace HospitalShijiazhuangPeople’s Republic of China
  4. 4.Blood transfusion divisionthe Fourth Hospital of Hebei Medical UniversityShijiazhuangPeople’s Republic of China

Personalised recommendations